| |||||||||
Former Names NOD.Cg-Tg(tetO-GFP/FADD)1Doi/DoiJ (Changed: 24-JAN-05 ) NOD.Cg-Tg(tetO-GFP/FADD)/DoiJ (Changed: 13-JAN-05 ) Type Congenic; Mutant Strain; Transgenic; Additional information on Genetically Engineered Mutant Mice. Species laboratory mouse Background Strain NOD/ShiLtJ Donor Strain B6SJLF2 H2 Haplotype g7 Donating Investigator Christophe Benoist, Joslin Diabetes Center Appearance
albino, pink-eyed
Related Genotype: A/? Tyrc/TyrcDescription
Mice hemizygous for this transgenic insert are viable, fertile, normal in size. Diabetes incidence and onset is similar to that observed in NOD inbred mice, but otherwise, the mice do not display any gross physical or behavioral abnormalities. These transgenic mutant mice may be mated to strains carrying either rtTA (reverse tetracycline trans-activator protein) or tTA (the tetracycline trans-activator) transgenes regulated by tissue specific promoters. In the bi-transgenic offspring of such crosses, tissue-specific expression of the EGFP/FADD fusion protein can be either induced (in rtTA transgenic mice) or suppressed (in tTA transgenice mice) by administration of the tetracycline analog, doxycycline (dox). Dox may be administered in the animals? water supply.Double transgenic mice generated by intercrossing Tg(tetO-EGFP/FADD)1Doi transgenic mice with NOD.Cg-Tg(Ins2-rtTA)2Doi/DoiJ (Stock No. 004602) transgenic mice express the EGFP/FADD fusion protein exclusively in the pancreatic β-cells in the presence of dox. Strikingly, only about 35% of the β-cells express the EGFP/FADD fusion protein in the presence of dox. (Vence L, Mathis D, Benoist C. 2004, graduate thesis, unpublished). Alternatively, when Tg(tetO-EGFP/FADD)1Doi transgenic mice are crossed with NOD.Cg-Tg(Ins2-tTA)1Doi/DoiJ (Stock No. 004937) the EGFP/FADD fusion protein is expressed in pancreatic b-cells, in the absence of dox, and its expression can be down-regulated by dox administration.
These two double transgenic systems can be used to study the influence of FADD in apoptosis of pancreatic β-cells.
Development
The fusion transgene tetO-EGFP/FADD is under the control of the tetracycline responsive promoter (TRE; tetO), and encodes a Fas associated death domain (FADD) molecule in which a full-length enhanced green florescent protein (EGFP) replaces the FADD death effector domain (amino acids 1-79) (Vence L, Mathis D, Benoist C. 2004, graduate thesis, unpublished). Wajant et al, 1998, provided the EGFP/FADD fusion product. The tetO-EGFP/FADD transgenic construct was microinjected into B6SJLF2 embryos, and the resulting transgenice founder was backcrossed onto the NOD background. In 2004, the Type 1 Diabetes Resource received NOD.Cg-Tg(tetO-EGFP/FADD)1Doi/DoiJ at generation N15. These animals were subsequently backcrossed once to NOD/ShiLtJ, and are maintained as Tg/? x Tg/?
| Control | ||
|---|---|---|
| Noncarrier | ||
| 001976 NOD/ShiLtJ | ||
| Considerations for Choosing Controls | ||
Fluorescent Protein Strains
View Fluorescent Protein Strains (170 strains)
Strains carrying other alleles of GFP
View Strains carrying other alleles of GFP (96 strains)
Strains carrying other alleles of tetO
View Strains carrying other alleles of tetO (28 strains)
Congenic Nomenclature
Fluorescent Proteins/lacZ Systems
Tet Expression Systems
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:
GFP relatedApoptosis Research
Death Receptors
Diabetes and Obesity Research
Type 1 Diabetes (IDDM) Analysis Strains (NOD Transgenics)
Research Tools
Apoptosis Research
Diabetes and Obesity Research
Fluorescent Proteins
Tet Expression Systems (tTA/rtTA Responsive Strains)
Research Tools
Fluorescent Proteins
| Allele Symbol | Tg(tetO-EGFP/FADD)1Doi | ||
|---|---|---|---|
| Allele Name | transgene insertion 1, Christophe Benoist | ||
| Allele Type | Transgenic (random, expressed) | ||
| Mutation Made By | Christophe Benoist, Joslin Diabetes Center | ||
| Strain of Origin | (C57BL/6 x SJL)F2 | ||
| Site of Expression | May be mated to strains carrying either rtTA or tTA transgenes regulated by tissue specific promoters for the study of tissue-specific expression of the EGFP/FADD fusion protein either induced (by the rtTA construct) or suppressed (by the tTA construct) by respective administration or removal of the tetracycline analog, doxycycline (Dox). | ||
| Expressed Gene | FADD, Fas (TNFRSF6)-associated via death domain, human | ||
| Expressed Gene | GFP, Green Fluorescent Protein, jellyfish | ||
| Green Fluorescent Protein (GFP), derived from the jellyfish Aequorea victoria, is a versatile reporter molecule which has found use in many biological applications. In some constructs the original molecule has been modified in order to enhance its fluorescence intensity (EGFP, enhanced GFP). When utilized in a transgenic construct, tissue expressing sufficient amounts of GFP will fluoresce when exposed to a 488 nm light source. | |||
| Promoter | tetO, tet operator, | ||
| Molecular Note | The transgene encodes a fusion protein consisting of a truncated, dominant-negative mutant Fas-associated death domain protein in which amino acids 1-79, constituting the death effector domain, have been replaced by the full-length enhanced green fluorescent protein. The coding sequence, preceded by a minimal CMV promoter and a rabbit beta-globin intron and followed by the beta-globin polyadenylation signal, resides downstream of seven copies of the tet operator (tetO). TetO, when present in cells also carrying a tetracycline transactivator (tTA) or reverse transactivator (rtTA) transgene, is inactivated or activated, respectively, by the administration of tetracycline. [MGI Ref ID J:94935] [MGI Ref ID J:95005] | ||
This strain will not have a genotyping protocol or one is not currently available.
Helpful Links
Optimizing PCR Protocols
Labrecque N; Whitfield LS; Obst R; Waltzinger C; Benoist C; Mathis D. 2001. How much TCR does a T cell need? Immunity 15(1):71-82. [PubMed: 11485739] [MGI Ref ID J:70595]
Tg(tetO-EGFP/FADD)1Doi relatedVence L; Mathis D; Benoist C. 1995. DN-FADD and Diabetes Personal Communication :. [MGI Ref ID J:95005]
Wajant H; Johannes FJ; Haas E; Siemienski K; Schwenzer R; Schubert G; Weiss T; Grell M; Scheurich P. 1998. Dominant-negative FADD inhibits TNFR60-, Fas/Apo1- and TRAIL-R/Apo2-mediated cell death but not gene induction. Curr Biol 8(2):113-6. [PubMed: 9427646] [MGI Ref ID J:94935]
Colony Maintenance
Diet Information LabDiet® 5K52/5K67
| Pricing for USA, Canada and Mexico shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $1900.00 Cryopreserved Embryos Fee $1600.00
| Pricing for International shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $2470.00 Cryopreserved Embryos Fee $2080.00
| Standard Supply | Repository-Cryopreserved. Must Be Recovered. Please refer to pricing and supply notes for further information. |
|---|---|
| Supply Notes |
|
| Control | ||
|---|---|---|
| Noncarrier | ||
| 001976 NOD/ShiLtJ | ||
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. THE LABORATORY EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.
In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.
MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.
Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.